In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Chimerix (NASDAQ:CMRX) with a price target of …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a price target …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41.00 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a $23.00 price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and slightly raised his price target to $390 (from …
